

EMPOWERING CLINICAL TRIALS WITH GENOMIC INSIGHTS FROM ASIA



ACT Genomics is a leading precision oncology company headquartered in Taipei. We provide comprehensive NGS testing and advanced bioinformatics solutions to support pharmaceutical and CRO partners. We enable seamless localization of genomics service, reducing cost, streamlining operations, and ensuring regulatory compliance across the APAC region.

Accreditations: CAP | LDTS | ISO15189 | ISO13485 | ISO27001 | ISO27701
Global Footprint: Taipei | Hong Kong | Thailand | Singapore | Japan | UK

Our Value Proposition

- CAP-accredited labs with high service success rate
- Potential CDx partner

**CLINICAL
TRIAL
PARTNER**

**DATA
PARTNER**

- AI-assisted analysis
- Asian database providing valuable insights

- Multi-Omics Capabilities
- Biomarker identification and product design experience

**TRANSLATIONAL
RESEARCH
PARTNER**

**ASSAY
TRANSFER
EXPERIENCE**

- Local/ regional labs setup caliber
- Regulatory experience across APAC region

Why Partner with Us

Proteogenomic Profiling

- Biomarker discovery
- Patient stratification & eligibility screening
- Tissue & liquid biopsy profiling for biomarker detection
- Rapid turnaround for timely trial enrollment

Data Analysis

- Advanced variant analysis and reporting
- Complex biomarker profiling (TMB, MSI, LOH, HRD, Fusions)
- Clinically curated Asian genomic database
- Experienced medical informatics support

Collaborative Approach

- Tailored models for pharma & CRO collaboration
- Pan-Asia lab network enabling faster turnaround with strong KOL engagement and regional support
- Reliable execution with quality-driven service delivery

Our Service Offerings

Product Name	Genes	Biomarker	When
ACT Onco [®] +	440	SNV/ InDel , CNV, MSI, TMB, Fusion	Advanced or Metastatic Seek <u>comprehensive</u> treatment options
ACT Liquid [™] Pro	523	SNV/ InDel , CNV, MSI, TMB, Fusion	Advanced or Metastatic Seek <u>comprehensive</u> treatment options. No tissue available
ACT Drug [®] +	101	SNV/ InDel , CNV, Fusion	Advanced or Metastatic Seek <u>immediate</u> treatment options
ACT Fusion [™]	13	Fusion	
ACT Lung [™]	13	SNV, Fusion	
ACT BRCA [®]	2	SNV/ InDel , LGR	Considering <u>PARPi</u> therapy
ACT HRD [™]	24	SNV/ InDel , CNV, LGR, HRD	
ACT Cerebra [™]	40	SNV/InDel	Metastatic to brain
ACT Monitor [®] +	50	SNV/InDel	For monitoring of response or recurrence
OncoOmicsDX Clinical Provenomics for Patient Care	30/72	Tumor-associated Proteins	Seek <u>personalized</u> treatment selection for chemotherapy, targeted therapy, and ADCs

Success Stories

Case I: Tailored clinical trial solution

ACT Genomics partnered with a leading biopharmaceutical company to develop a tailored solution for a clinical trial, integrating both wet- and dry-lab processes. We adapted swiftly to evolving needs and delivered high-quality results that exceeded expectations and paved way for future collaborations.

Case II: Preferred Genomic Testing Partner

ACT Genomics collaborated with an international full-service CRO to provide patient pre-screening prior to trial enrollment. Through timely execution, reliable service delivery, and consistent performance, we became a certified local provider and the client's preferred laboratory partner for future genomic testing projects.

” **Bridging local testing capabilities
with global clinical research initiatives** ”

Contact Us

ACT Genomics Co., Ltd.

- Website: www.actgenomics.com
- Email: service@actgenomics.com
- Business Development Contact: BD@actgenomics.com
- Headquarters – Taipei, Taiwan

